Skip to content

Comparing the efficacy of Ibuprofen and Celecoxib on the intensity of perineal pain following episiotomy

Comparing the efficacy of Ibuprofen and Celecoxib on the intensity of perineal pain following episiotomy: a single blind, randomized clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201106136790N1
Enrollment
170
Registered
2012-08-14
Start date
2009-03-30
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post episiotomy pain. Other complications of obstetric surgery and procedures

Interventions

Intervention 1: Ibuprofen (400 mg), every 6 and 12 hours as necessary. Intervention 2: Celecoxib (100mg), orally, 6 and 12 hours as necessary.
Treatment - Drugs
Ibuprofen (400 mg), every 6 and 12 hours as necessary
Celecoxib (100mg), orally, 6 and 12 hours as necessary

Sponsors

Ilam University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1-18-35 y/o; 2-mediolateral episiotomy; 3-singleton; 4- alive fetus. Exclusion criteria: 1-sensitivity to NSAIDs; 2-history of digestive system disorders; 3-presence of chronic illness; 4-rupture of cervix; 5-post partum hemorrhage; 6-pre eclampcia and eclampcia; 7-PROM.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain severity. Timepoint: pre intervention,1, 2, 4, 8 and 12 hours after intervention. Method of measurement: VAS.

Secondary

MeasureTime frame
Digestive system complications. Timepoint: Every 12 hours. Method of measurement: History and Physical exam.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZainab Suhrabi

Ilam University of Medical Sciences

suhrabi-z@medilam.ac.ir ; suhrabi2007@yahoo.com+98 84 1222 7123

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026